Focused On-demand Library for Large ribosomal subunit protein uL24

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P61254

UPID:

RL26_HUMAN

Alternative names:

60S ribosomal protein L26

Alternative UPACC:

P61254; B2R4F0; D3DTR8; Q02877; Q6IPY2

Background:

The Large ribosomal subunit protein uL24, also known as 60S ribosomal protein L26, is a crucial component of the large ribosomal subunit. This protein plays a pivotal role in the synthesis of proteins within the cell, a process fundamental to cellular function and growth. Its presence in the ribosome underscores its importance in translating genetic information into functional proteins.

Therapeutic significance:

Diamond-Blackfan anemia 11, a congenital non-regenerative hypoplastic anemia, is directly linked to mutations affecting the gene encoding Large ribosomal subunit protein uL24. This association highlights the protein's critical role in hematopoiesis and underscores the potential for targeted therapeutic strategies aimed at correcting the underlying genetic defects.